Peter Valent. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. haematol [Internet]. 2011Oct.4 [cited 2024Nov.22];96(10):1395-7. Available from: https://haematologica.org/article/view/6083